Human Immunodeficiency Virus Infectious Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HMN014 MIFTS: 53	Human Immunodeficiency Virus Infectious Disease Categories: Immune diseases, Infectious diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease ¹¹ ¹⁴

Hiv Infections ¹⁴

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Human immunodeficiency virus [HIV] disease

Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases

External Ids:

Disease Ontology ¹¹ DOID:526

ICD9CM ³⁴ 042-042.99

MeSH ⁴³ D015658

NCIt ⁴⁹ C3108

SNOMED-CT ⁶⁸ 86406008

ICD10 ³¹ B20

UMLS ⁷¹ C0019693

Sources

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology: ¹¹ A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary: Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to acquired immunodeficiency syndrome and human immunodeficiency virus type 1. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lercanidipine and Candesartan cilexetil have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and liver, and related phenotypes are neoplasm and endocrine/exocrine gland

Sources

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 588)

#	Related Disease	Score	Top Affiliating Genes
1	acquired immunodeficiency syndrome	32.6	TNF ITIH4 IL2 IL10 IFNG IFNA1
2	human immunodeficiency virus type 1	31.5	ITIH4 IL7 IL2 IL10 IFNG ERVW-1
3	syphilis	31.4	TNF CD4 CD209 CCR5 B2M
4	chlamydia	31.1	TNF IL10 IFNG CCR5
5	candidiasis	31.0	TNF IL2 IL10 IFNG
6	pneumocystosis	31.0	TNF IL2 IL10 IFNG CD4
7	immune deficiency disease	31.0	TNF ITIH4 IL7R IL7 IL2 IL10
8	hepatitis c	30.9	IL10 IFNG IFNA1 CD209
9	viral infectious disease	30.9	TNF ITIH4 IL7R IL7 IL2 IL10
10	hepatitis a	30.9	TNF IL10 IFNG IFNA1 CD4 CCR5
11	toxoplasmosis	30.8	TNF IL10 IFNG CCR5 CCL3
12	herpes zoster	30.8	IL2 IL10 IFNG IFNA1 CD4 CCR5
13	oral hairy leukoplakia	30.8	ITIH4 IL10 CD4
14	trichomoniasis	30.7	TNF IL10 CD4 CCR5 CCL5 CCL4
15	diarrhea	30.7	TNF IL2 IL10 IFNG IFNA1
16	peripheral nervous system disease	30.7	TNF IL2 IL10 IFNG IFNA1 CXCR4
17	secondary syphilis	30.7	TNF CD4 CCR5
18	anogenital venereal wart	30.6	TNF IL2 IFNA1 CD4
19	anterior uveitis	30.6	TNF IL2 IL10 IFNG CD4
20	mycobacterium tuberculosis 1	30.6	TNF IL7 IL10 IFNG CXCR4 CD4
21	bacterial pneumonia	30.6	TNF IL10 IFNG CD4 CCL3
22	bacterial vaginosis	30.6	TNF IL10 CD4 CCR5 CCL5 CCL4
23	uveitis	30.6	TNF IL2 IL10 IFNG CCR5 CCL4
24	otitis media	30.6	TNF IL2 IL10 IFNG CCL5
25	skin disease	30.6	TNF IL7R IL7 IL2 IL10 IFNG
26	cytomegalovirus retinitis	30.6	TNF IL10 IFNG CXCL12 CD9 CD4
27	lymphoma, non-hodgkin, familial	30.5	IL7 IL2 CXCR4 CXCL12 CD4 CD38
28	deficiency anemia	30.5	TNF IL2 IL10 IFNA1 CD4 CD38
29	acute retinal necrosis syndrome	30.4	TNF IL10 CD4
30	dermatitis	30.4	TNF IL2 IL10 IFNG
31	choroiditis	30.4	TNF IL10 IFNG CD4
32	keratoconjunctivitis	30.4	TNF IL2 IFNG CCR5
33	plague	30.4	TNF IL2 IL10 CD4 CCR5
34	pneumonia	30.4	TNF IL10 IFNG CCL5 CCL3
35	aphthous stomatitis	30.4	TNF IL2 IL10 IFNG CD4
36	posterior uveitis	30.4	TNF IL2 CD4
37	blepharitis	30.4	TNF IL2 CD4
38	septic arthritis	30.4	TNF IL10 CD4
39	human cytomegalovirus infection	30.4	TNF IL10 CD4
40	parasitic helminthiasis infectious disease	30.4	TNF IL2 IL10 IFNG CD4
41	extrinsic allergic alveolitis	30.4	TNF CD4 CCL5 CCL3 B2M
42	lymphoid interstitial pneumonia	30.4	TNF IL2 IFNG CD4 B2M
43	meningoencephalitis	30.4	TNF IL10 CD4 CCL5 B2M
44	anus disease	30.4	TNF IL2 CD4
45	toxic shock syndrome	30.4	TNF IL2 IL10 IFNG
46	conjunctivitis	30.4	TNF IL7 IL2 IL10 IFNG
47	gingivitis	30.4	TNF IL2 IL10 IFNG CCL5
48	periodontitis	30.4	TNF IL2 IL10 IFNG
49	aseptic meningitis	30.4	TNF IL10 IFNA1 CD4 CCL3
50	endocarditis	30.4	TNF IL10 IFNG CCL4

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:

Sources

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

GenomeRNAi Phenotypes related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	B2M CCL3 CCL4 CCL5 CCR5 CD209
2	no effect	GR00402-S-2	10.18	B2M CCL3 CCL4 CCL5 CCR5 CD209

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.16	B2M CCR5 CD9 CXCR4 IFNG IL10
2	endocrine/exocrine gland	MP:0005379	10.15	B2M CD38 CD4 CD9 CXCR4 IFNG
3	cellular	MP:0005384	10.13	B2M CCL3 CCR5 CD209 CD38 CD4
4	immune system	MP:0005387	10.09	B2M CCL3 CCL5 CCR5 CD209 CD38
5	digestive/alimentary	MP:0005381	10.02	B2M CCL3 CCR5 CD209 CD4 CXCR4
6	liver/biliary system	MP:0005370	10.01	B2M CCR5 CXCL12 IFNG IL10 IL2
7	no phenotypic analysis	MP:0003012	9.98	CD4 CXCL12 IFNG IL10 IL2 IL7
8	respiratory system	MP:0005388	9.56	CCR5 CD9 CXCR4 IFNA1 IFNG IL10
9	hematopoietic system	MP:0005397	9.55	B2M CCL3 CCL5 CCR5 CD209 CD38

Sources

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 808)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lercanidipine

Approved, Investigational

Phase 4

100427-26-7

65866

Candesartan cilexetil

Approved

Phase 4

145040-37-5

Zalcitabine

Approved, Investigational

Phase 4

7481-89-2

24066

Didanosine

Approved

Phase 4

69655-05-6

50599

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4

52485-79-7, 53152-21-9

644073 40400

Trimethoprim

Approved, Vet_approved

Phase 4

738-70-5

5578

Sulfamethoxazole

Approved

Phase 4

723-46-6

5329

Lopinavir

Approved

Phase 4

192725-17-0

92727

Entecavir

Approved, Investigational

Phase 4

142217-69-4

153941

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 4

595-33-5

11683

Mupirocin

Approved, Investigational, Vet_approved

Phase 4

12650-69-0

446596

Elvitegravir

Approved

Phase 4

697761-98-1

23083982 5277135

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 4

14838-15-4, 492-39-7

131954576 4786 26934

Methadone

Approved

Phase 4

76-99-3, 1095-90-5

4095

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Indinavir

Approved

Phase 4

150378-17-9

5362440

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Fosamprenavir

Approved

Phase 4

226700-79-4

131536

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Pravastatin

Approved

Phase 4

81093-37-0

54687

Vincristine

Approved, Investigational

Phase 4

2068-78-2, 57-22-7

5978

Zoledronic acid

Approved

Phase 4

118072-93-8

68740

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Zinc sulfate

Approved, Investigational

Phase 4

7733-02-0

Atovaquone

Approved

Phase 4

95233-18-4

74989

Proguanil

Approved

Phase 4

500-92-5

4923 6178111

Sofosbuvir

Approved

Phase 4

1190307-88-0

45375808

Famotidine

Approved

Phase 4

76824-35-6

3325 5702160

Artenimol

Approved, Experimental, Investigational

Phase 4

71939-50-9

540327

Piperaquine

Approved, Experimental, Investigational

Phase 4

4085-31-8

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 4

58-14-0, 19085-09-7

4993

Sulfadoxine

Approved, Investigational

Phase 4

2447-57-6

17134

Modafinil

Approved, Investigational

Phase 4

68693-11-8

4236

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Cytarabine

Approved, Investigational

Phase 4

147-94-4

6253

Doxepin

Approved, Investigational

Phase 4

1668-19-5

667468 667477

Temazepam

Approved, Investigational

Phase 4

846-50-4

5391

Amprenavir

Approved, Investigational

Phase 4

161814-49-9

65016

Aminosalicylic acid

Approved

Phase 4

65-49-6

4649

Ketoconazole

Approved, Investigational

Phase 4

65277-42-1, 142128-57-2

47576 3823 638701

Foscarnet

Approved

Phase 4

63585-09-1, 4428-95-9

3415

Clarithromycin

Approved

Phase 4

81103-11-9

84029

Itraconazole

Approved, Investigational

Phase 4

84625-61-6

55283

Valganciclovir

Approved, Investigational

Phase 4

175865-60-8

64147

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

Interventional clinical trials:

(show top 50) (show all 5231)

#	Name	Status	NCT ID	Phase	Drugs
1	Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda	Unknown status	NCT00674921	Phase 4	cotrimoxazole;Placebo
2	A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects	Unknown status	NCT00740064	Phase 4	Raltegravir and Abacavir/Lamivudine
3	Efecto de la Isoprinosina en Pacientes Con infección Por VIH y Carga Viral Entre > 50 y < 200 Copias/mL de la Unidad de atención de PVV Del Hospital Enrique Garcés en Quito, Ecuador Durante el año 2019.	Unknown status	NCT03883334	Phase 4	Metisoprinol
4	Multicenter, Open, Pilot Clinical Trial Aimed to Compare the Efficacy of RAL1200 QD vs DRV-cb 800-150 QD Both in Combination With TAF/FTC in Patients With HIV Infection and CD4 Count Under 200 Cells/microL	Unknown status	NCT03842488	Phase 4	Experimental: RAL QD;Active comparator: DRV/cb
5	Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.	Unknown status	NCT00751153	Phase 4	Raltegravir and Atazanavir
6	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	Unknown status	NCT00426296	Phase 4	atazanavir (Reyataz);ritonavir (Norvir)
7	A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study	Unknown status	NCT04076423	Phase 4	Dual Therapy;Triple therapy
8	Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study	Unknown status	NCT03732625	Phase 4	Raltegravir
9	Impact of HIV-1 and Aging on Mucosal Vaccine Responses	Unknown status	NCT03729778	Phase 4
10	Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study)	Unknown status	NCT03682939	Phase 4
11	Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects	Unknown status	NCT00759070	Phase 4	Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
12	Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study.	Unknown status	NCT00843661	Phase 4	ezetimibe;fenofibrate;pravastatin
13	A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication	Unknown status	NCT00840762	Phase 4
14	Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring	Unknown status	NCT00836212	Phase 4	Reducing dose of Lopinavir;Reducing dose of efavirenz
15	Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860	Unknown status	NCT02008214	Phase 4	Pentoxifylline;Placebo
16	An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings	Unknown status	NCT00124358	Phase 4	Buprenorphine
17	Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients	Unknown status	NCT00872417	Phase 4	first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
18	MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)	Unknown status	NCT00122226	Phase 4	Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
19	A Phase IV, Open-label, Multicenter and Single-arm on the Immunogenicity of Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017	Unknown status	NCT03626467	Phase 4
20	Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients	Unknown status	NCT00620438	Phase 4	Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
21	A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive	Unknown status	NCT00005017	Phase 4	Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
22	A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients	Unknown status	NCT00005000	Phase 4	Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
23	Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)	Unknown status	NCT04054089	Phase 4	Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy];dolutegravir 50 mg / lamivudine 300 mg
24	Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy	Unknown status	NCT01059422	Phase 4	Raltegravir; Abacavir/Lamivudine
25	A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects	Unknown status	NCT00011895	Phase 4	Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
26	Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine	Unknown status	NCT00564057	Phase 4	candesartan;lercanidipine
27	An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone	Unknown status	NCT01105611	Phase 4	Raltegravir;Atazanavir/Ritonavir
28	SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model	Unknown status	NCT00241930	Phase 4
29	Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS)	Unknown status	NCT00941083	Phase 4	Raltegravir (Use RAL as a simplification strategy)
30	Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study	Unknown status	NCT01049685	Phase 4	First-line Antiretroviral Therapy
31	Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI) Treated With Multitarget Antiviral Therapy (MT-ART)	Unknown status	NCT04225325	Phase 4
32	A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART	Unknown status	NCT02659761	Phase 4	dolutegravir/abacavir/lamivudine
33	Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus	Unknown status	NCT00797030	Phase 4	cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
34	Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan	Unknown status	NCT03855176	Phase 4	Vaqta Injectable Product
35	Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department	Unknown status	NCT03711253	Phase 4	Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
36	Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach	Unknown status	NCT01875952	Phase 4	Isoniazid
37	Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE)	Unknown status	NCT04249037	Phase 4	bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF);Standard initiation of antiretroviral therapy (ART)
38	Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed	Unknown status	NCT04132674	Phase 4	Bictegravir/emtricitabine/tenofovir alafenamide
39	Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults	Unknown status	NCT03041051	Phase 4
40	Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease	Unknown status	NCT00162643	Phase 4	zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
41	Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)	Unknown status	NCT00120419	Phase 4	mycophenol mofetil (MMF, Cellcept®) 500 mg BID
42	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).	Unknown status	NCT02337322	Phase 4	Dolutegravir;Darunavir/r
43	A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily	Unknown status	NCT00214435	Phase 4	once daily minimum 3-drug regimen of anti-retroviral medications
44	Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B	Unknown status	NCT03120494	Phase 4	Emtricitabine and Tenofovir
45	A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART	Unknown status	NCT01230580	Phase 4	Protease Inhibitor;Standard-of-care Antiretroviral therapy
46	Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection	Unknown status	NCT01343225	Phase 4	atripla;darunavir ritonavir raltegravir
47	Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml	Unknown status	NCT01453933	Phase 4	raltegravir
48	Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection	Completed	NCT00662545	Phase 4	Entecavir with continued standard of care antiretroviral therapy;continued standard of care with tenofovir in addition to emtricitabine or lamivudine
49	Efficacy and Safety of Switching From AZT to Tenofovir	Completed	NCT00647244	Phase 4	Tenofovir disoproxil fumarate;Abacavir
50	Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation	Completed	NCT03314064	Phase 4	Dolutegravir 50 mg

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Sources

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Sources

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

Organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

MalaCards : T Cells, Breast, Liver, Lymph Node, Bone Marrow, Endothelial, Bone

Sources

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 7362)

#	Title	Authors	PMID	Year
1	Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). ⁵³ ⁶²	Workman S...Granade TC	19482361	2009
2	Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. ⁵³ ⁶²	Pandori MW...Klausner JD	19535523	2009
3	Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). ⁵³ ⁶²	Mirzaei M...Prakash S	18546077	2008
4	Emerging antiviral drugs. ⁵³ ⁶²	De Clercq E	18764719	2008
5	A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. ⁵³ ⁶²	Healan-Greenberg C...Kim RB	18096673	2008
6	A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. ⁵³ ⁶²	Lund N...Lingwood CA	16439866	2006
7	Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. ⁵³ ⁶²	Rosas-Taraco AG...Salinas-Carmona MC	16438645	2006
8	RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. ⁵³ ⁶²	Nair MP...Sykes D	16353935	2005
9	Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. ⁵³ ⁶²	Nair MP...Schwartz SA	14741421	2004
10	Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. ⁵³ ⁶²	Zheng BJ...Lee SS	12461425	2002
11	Oral mucosal immunity and HIV infection: current status. ⁵³ ⁶²	Challacombe SJ...Sweet SP	12164661	2002
12	Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. ⁵³ ⁶²	Capini CJ...Rappaport J	11237281	2001
13	Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. ⁵³ ⁶²	Kourtis AP...Lee FK	11101052	2000
14	Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. ⁵³ ⁶²	Xu Y...Hattori T	10195751	1999
15	[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]. ⁵³ ⁶²	Yerly S...Perrin L	10189669	1999
16	Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. ⁵³ ⁶²	Brenner BG...Wainberg MA	10231014	1999
17	Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ⁵³ ⁶²	Brockmeyer NH...Goos M	9612607	1998
18	New perspectives for the treatment of HIV infections. ⁵³ ⁶²	De Clercq E	9646721	1998
19	The role of biological response modifiers on apoptosis in HIV infections and AIDS. ⁵³ ⁶²	Koech DK	17451286	1996
20	Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. ⁵³ ⁶²	Campbell AP...Dyson HJ	9079375	1996
21	Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. ⁵³ ⁶²	Nair MP...Schwartz SA	7583919	1995
22	Zinc and immune function. ⁵³ ⁶²	Ripa S...Ripa R	7478075	1995
23	Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. ⁵³ ⁶²		7946101	1994
24	[Interferon-gamma. Therapy of recurrent furunculosis in HIV infections]. ⁵³ ⁶²	Thoma-Greber E...Plewig G	8104915	1993
25	Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion. ⁵³ ⁶²	Courouce AM...Elghouzzi MH	1492941	1992
26	Chemsex and incidence of sexually transmitted infections among Canadian pre-exposure prophylaxis (PrEP) users in the l'Actuel PrEP Cohort (2013-2020). ⁶²	Flores Anato JL...Maheu-Giroux M	35039437	2022
27	Brief Report: Use of Pre-Exposure Prophylaxis to Prevent Rapid HIV Transmission Among People Who Inject Drugs in Rural Counties in the United States: A Modeling Study. ⁶²	Jacka BP...Marshall BDL	36150038	2022
28	HIV and adolescent girls and young women in sub-Saharan Africa: A call for expedited action to reduce new infections. ⁶²	Murewanhema G...Dzinamarira T	36147901	2022
29	Evaluating the time of HIV infection, diagnosis and treatment delays based on HIV notification data in Northwest China, 2008–19. ⁶²	Zhao R...Zhuang G	36170977	2022
30	Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. ⁶²	Jamieson L...Meyer-Rath G	36356603	2022
31	Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care. ⁶²	Van Beckhoven D...Belgian Research on AIDS and HIV Consortium (BREACH)	36463126	2022
32	Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. ⁶²	Stone J...Vickerman P	36111533	2022
33	Preexposure Prophylaxis for HIV Prevention in a Rural Southern Clinic. ⁶²	Harrison RL...Fadul N	36455891	2022
34	HIV Services and Outcomes During the COVID-19 Pandemic - United States, 2019-2021. ⁶²	Hoover KW...Kourtis AP	36454696	2022
35	Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention? ⁶²	Liegeon G...Ghosn J	36468218	2022
36	Liver Transplantation in HIV-Infected Patient. ⁶²	Dogar AW...Ahmed HB	36474393	2022
37	Challenges with couples HIV counselling and testing among black MSM students: perspectives of university students in Durban, South Africa. ⁶²	Gumindega GC...Maharaj P	35912646	2022
38	Correlates of HIV Testing across the lifespan - adolescence through later adulthood - among sexual minority men in the US who are not on PrEP. ⁶²	Dellucci TV...Starks TJ	35916966	2022
39	Intersecting Communities and PrEP Uptake among US-based Latinx Sexual Minority Men. ⁶²	Robles G...Starks TJ	34554441	2022
40	'Oh, I don't really want to bother with that:' gay and bisexual young men's perceptions of barriers to PrEP information and uptake. ⁶²	Birnholtz J...Moskowitz DA	34524938	2022
41	Combining the HYM (Healthy Young Men's) Cohort Study and the TRUTH (A Trans Youth of Color Study): Protocol for an Expanded Mixed Methods Study Renewal. ⁶²	Azucar D...Kipke MD	36326811	2022
42	Eligibility criteria vs. need for pre-exposure prophylaxis: a reappraisal among men who have sex with men in Amsterdam, the Netherlands. ⁶²	de la Court F...Prins M	36440637	2022
43	Validation of HIV Pre-Exposure Prophylaxis (PrEP) Medication Scales with Youth on PrEP: PrEP Confidence Scale and PrEP Difficulties Scale. ⁶²	Budhwani H...Hightow-Weidman LB	36306520	2022
44	PrEP use and stigma among a sample of older adults in Columbus, Ohio. ⁶²	Morgan E...Ricks J	36424190	2022
45	Experiences of Mothers Living With HIV in a South African Prevention of Mother-to-Child Transmission of HIV Programme: A Qualitative Descriptive Study. ⁶²	Velapi L...Frantz J	36355599	2022
46	CD20+ T cells: an emerging T cell subset in human pathology. ⁶²	Lee AYS	35951029	2022
47	Recent HIV Infection Among Men Who Have Sex with Men, Transgender Women, and Genderqueer Individuals with Newly Diagnosed HIV Infection in Zimbabwe: Results from a Respondent-Driven Sampling Survey. ⁶²	Parmley LE...Rogers JH	35923140	2022
48	Transmission network and phylogenetic analysis reveal older male-centered transmission of CRF01_AE and CRF07_BC in Guangxi, China. ⁶²	Zhang F...Liang B	36369697	2022
49	Distribution of HIV Self-tests by Men Who have Sex with Men (MSM) to Social Network Associates. ⁶²	Patel SN...eSTAMP study group	36318431	2022
50	Tele-counseling based on motivational interviewing to change sexual behavior of women living with HIV: a randomized controlled clinical trial. ⁶²	Talebi-Tamijani Z...Kabir K	35467228	2022

Sources

Genes for Human Immunodeficiency Virus Infectious Disease

Genes related to Human Immunodeficiency Virus Infectious Disease (0 elite genes):

(show top 50) (show all 73)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CCR5	C-C Motif Chemokine Receptor 5	Protein Coding	20.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16905787 18221152 9768623 (more) 12815099 16329283 10428111 19290034 14607877 10823791 9050881 12621126 15554931 11485615 9949155 9464809 11786906 17625759 11604406 9548484 9449724 9621031 9623113 15757671 16954729 18648518 11180099 11023494 10967018 10479136 10082117 9928734 9412701 20065862 18653488 12800065 12557141 12461425 12462390 11994538 11546936 11188946 10720514 10438347 12709027 12500303 11930315 11385319 11181160 11175286 9738921 9683255 9639073 15196257 11563633 11061648 10984119 20413825 19446719 18846999 17885304 17690574 15295615 17668369 17066899 16107768 15761117 15727489 14963124 14723967 12792869 19538721 18462992 18353949 11709782 11466389 11375057 10860879 10772093 10203028 9416501 9323208 19886831 19260142 19187693 16405836 15793360 10333239 9284370 19577762 16478397 15052642 12402506 11692670 11594685 18333870 16249699 15807900 10820198 11698309
2	CD4	CD4 Molecule	Protein Coding	20.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1706342 1983967 1674171 (more) 11689637 2103863 7524738 9480981 9621031 1548763 9749981 12639247 11075414 10096199 9583357 1281202 1942569 15043201 2297204 19020526 19066282 11943153 11906183 2041962 2150793 9501224 1676689 9949155 9684862 8871625 17066899 12709027 9035140 8707350 8601461 11180099 1319711 2045686 12514409 20088758 20147519 1704060
3	ITIH4	Inter-Alpha-Trypsin Inhibitor Heavy Chain 4	Protein Coding	19.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9295204 1706342 12775419 (more) 20088758 2006155 1701782 8543839 11504923 7521897 15807900 8100569 9671218 11060751 11125889 10333239 9108403 8423065 1518160 2297204 15943860 15109955 12379366 10477718 9744279 8620895 1993748 17522223 9343181 18353949 10381499 9806756 16439866 12960238 11514907 10922058 9927761 9779929 8022334 2380554 17211992 10665489 7583919 1381203 1537336 11294665 11085902 9583357 9120313 7522715 8461978 1283721 1281202 1592430 18020501 9749981 9186785 1907354 19736361 19781539 18160012 9079375
4	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	17.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9108384 14741421 10779364 (more) 9050881 10823791 15028427 9892690 9646721 10820198 11180099 18359010 19066282 9738921 9683255 9639073 19594447 11278278 19187693 12800065 11994538 19787093 17266557 15554931 15196257 11937572 11563633 11485615 10050701 19885584 17066899 18682304 17266570 12555203 12210401 11943153 11811784 9759835 9348282 11472251 10770963 10397558 10381170 10195751 9379028 9261420 17767733 15978137 16107768 15748209 15000561 12792869 12709027 11175286 9845516 18523757 11594685 11023494 20065862 16249699 11146046 14612668
5	IL2	Interleukin 2	Protein Coding	16.82	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12666584 15577620 15242957 (more) 8721559 16818697 11361933 10436654 8409454 11998783 15259908 1354168 16606671 9191868 8857018 8827221 12149467 8984220 16871325 9928725 11559831 11424973 2205261 7561117 7479922 9151380 9225990 9242543 12699419 10989965 10930145 10647974 8892656 7646690 7646637 19238075 17721096 15650365 9129987 7791831 7994626 8137559 8500265 1361339 1434984 1424272 1708701 11564594 11059640 10371491 10360808 11366777 8706325 8744576 7912546 19372787 8086133 2162775 19828532 18020597 16826155 14682073 11756982 10889599 10381168 8574145 7594657 7719919 10353861 11082734 9747746 8924248 7656123 20179574 18473782 17484210 16962051 16847417 15115314 14607921 10772528 10534144 10682140 9389737 9240622 11361533 7863815 8011237 18417356 15024180 10029242 9457191 1696861 20186278 19508157 18453567 16847956 12687247 12963692 11424974
6	CCL4	C-C Motif Chemokine Ligand 4	Protein Coding	16.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9732062 9649315 10461827 (more) 11120614 10225222 12500303 19758271 19058580 9566795 10364178 11289705 9466518 10497106 10820198
7	CD9	CD9 Molecule	Protein Coding	16.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9403423 14646380 8207645 (more) 8604210 1335543 8461467 9820572 16027784 19482361 1878399 7719918 1688087 2252248 1972189 18322614 15135738 10609356 9743066 9704953 7576319 11322416 11256731 10207549 9665998 15566855 7546416 7913814 8209132 8310487 1904161 17182760 15532188 12960819 12152521 10189669 9243042 7561186 1362093 9402068 8419814 20301999 16791011 11400767 9240857 8671325 8097417 1753339 1744591 19535523 12004270 11064116 7910149 8141193 1492941 1883515 16313975 1504207 1673465 12423700 10917776 9421770 7664172 8091747 8097416 8000258 1501285 20003901 18194389 10655373 1408485 8035017
8	IFNG	Interferon Gamma	Protein Coding	15.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8409454 8083609 14980074 (more) 9950887 1424271 10436654 9353145 8984220 9184702 16352578 10094326 7583443 18025876 7719919 9264291 9207360 8094160 7526793 7561117 8732485 8104915 9892533 17498423 11782589 11595301 11556760 11518830 10930145 10685075 9949171 10600293 9227322 7474452 8090535 8258154 1354651 2253685 12202149 10358896 9389737 14694094 11429120 11372024 10419892 10225828 9566795 9317163 9233457 9132281 15964028 15090789 15036244 12555203 11559831 11193591 9607833 9342066 8862284 19479058 19156218 8836919 8554705 8163831 1730155 1691289 18644020 16289324 15332430 7583919 7911045 1392441 1940975 15043212 10444266 9949155 8827221 8728056 8924248 7797233 8149667 20179574 10933622 10413659 10358209 9240622 9604776 17331033 11494161 9129987 8923089 7994626 20302657 9875576 7800944 7903382 16227806 19692459 1586484 1400376
9	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	15.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10917892 17671228 12634395 (more) 16437690 9247020 10820198 10875609 12543882 16478397 11125885 16438645 9566795 9120310 19758271 10505676 10364178 9024986 16897666 11289705 11120614 20197549 10876908 20164782 10364494 10461827
10	B2M	Beta-2-Microglobulin	Protein Coding	15.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1398802 18610664 2059368 (more) 8002043 1569212 7946101 9078471 1909873 8097416 8707483 10959644 10374184 7583848 7567807 7919434 8104488 7904317 12734931 12420343 9402068 8163831 8103715 1346807 2196662 7932082 1687609 1776713 1969960 7959371 1941351 1895208 9049785 1350951 1351128 8898671
11	CCL3	C-C Motif Chemokine Ligand 3	Protein Coding	15.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11120614 10875609 18332855 (more) 18221152 9333424 12500303 10364178 8634452 10779806 9566795 19758271 9024986 11289705 12621126 10461827 10497106
12	ERVW-1	Endogenous Retrovirus Group W Member 1, Envelope	Protein Coding	15.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1984680 7903106 10922058
13	TNF	Tumor Necrosis Factor	Protein Coding	15.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8002043 19347588 1453335 (more) 8897887 10996387 8340891 17287559 17321777 11207298 8618848 2355883 11426066 9084788 8828740 9144590 7627624 7707730 1657073 1901834 2147539 11237281 1564486 1376041 1325303 8078736 9017151 12427285 18643751 10720518 9875576 9641613 8566032 7800944 7903382 1725130 1891985 1709966 11525154 10403920 9874667 9087512 8931778 8737706 8786725 8409454 8419084 8258154 1295450 20298670 17982088 16289751 15596754 15115314 14727985 9814454 1392441 1814326 1940975 20152054 17210815 16623632 16352578 15075543 12009086 7704970 7800946 8347399 10839591 15538818 9330861 7797233 20492885 12850163 10786999 10092829 9670954 9456687 8977931 8984220 8519449 7827153 8090535 8169428 9519890 8088326 1586135 1768380 1996584 20122243 17721110 15541398 1283718 1414560 1640166 1985116 2171598 20197549 12687247 10823791
14	IL10	Interleukin 10	Protein Coding	14.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8844018 10209514 18643751 (more) 8610180 12468426 8409454 8990099 20440075 9498436 9342066 7627624 12243799 7600105 7561117 9449724 8883145 9875576 11518830 12734931 12202149 9240622 11197608 10403920 10436654 7994626 20197549 16437243 8827221 8728056 8924248 7848677 7908324 19010320 17484210 17312176 15021309 10094326 9808566 9271184 8828740 18282273 17202341 12414752 11298493 11110048 9096366 9132281 8086133 16920714 11044099 9933090 10360808 8706325 8656012 1354651 20208540 20298670 15937058 14980074 11833470 10712670 9353145 8870845 12270545 9151380 8695805
15	IL7	Interleukin 7	Protein Coding	14.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19372891 12847229 11590518 (more) 9562375 15259908 19239367 20304824 12634395 12653844 15141001 17404319 19529752 18417032 15090811 19432535 15709041 15627636 19060209 18441236 17168832 19864382 19372787 16464744 16542695 11590936 17053062 9395008 18546077
16	CD209	CD209 Molecule	Protein Coding	14.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15905500 15579280 12414925 (more) 19879650 20085340 12562327 17530994 12270546 16353935 15545354 19046307 17522223 15802983 11312337 12152166
17	IFNA1	Interferon Alpha 1	Protein Coding	14.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1371692 1573319 1971503 (more) 7526793 7852835 17451286 10691920 19692459 16791012 1729362 8746078 8887055 8603961 16816552 18650129 8027590 20145197 18370866 11772539 9017150 8419084 1716779 2264889 18806124 14689754 7797233 1657073 1883515 2135379 2230256 1976701 14720084 12845770 8903853 7553219 8163831 1381599 11546934 10202561 11729827 9568721 7583919 16908514 12390316 11392964 11193591 8892737 8823848 7719919 7694057 1381203 19949061 19706714 16117865 15962225 15767412 12187507 12847309 11585000 11504966 10544084 9629309 9612607 9389973 16916960 11091068 1709966 9067644 9837796 12457982 12543882
18	CD38	CD38 Molecule	Protein Coding	14.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9358102 8671648 1418775 (more) 8809474 15558452
19	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	14.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20104779 12215924 9108384 (more) 10413364 10479136 10602722 16478397 19787093 12500303 15748209 12192272 9708910 19758271 12787886 11865429 9744279 18483105 17673719 15978137 11943153 12834106 10486323 14502291 18495324 9546575 10381499 11709782
20	IL7R	Interleukin 7 Receptor	Protein Coding	14.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16421946 18964017 18390743 (more) 11744834 16260904 17956896 19864382 18847371 20304824 16284456 20520721
21	CD28	CD28 Molecule	Protein Coding	14.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9029089 7973455 12792869 (more) 14984593 7539725 16826489 9328114 16267766 8229654 8803949 20104487
22	APOBEC3G	Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G	Protein Coding	13.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17067930 15723516 16418394 (more) 17917584 16250885 19254362
23	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	13.54	DISEASES inferred ¹⁴ ¹⁴
24	IL4	Interleukin 4	Protein Coding	13.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8977228 9353145 10436654 (more) 9342066 12513914 8827221 7561117 11881490 7732782 11180099 20201040 7807023 9129987 10360808 9227322 16943383 12202149 11268427 9389737 9240622 17721110 17331033 9728536 9607833 9271184 19382262 12515722 9233457 9132281 16987060 9933090 9264144 8924248 7540885 8149667 15021309 9084802 7994626 12687247 10712670 7916030 7869194 7718882
25	IL15	Interleukin 15	Protein Coding	13.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9949171 11807301 9190952 (more) 15036244 16289324 10731928 11079620 16022657 18417356 14684414 18523260 18417032 15795273 10556978 8877133 9793826 15141001 10394054 9933090 10961903
26	CCR3	C-C Motif Chemokine Receptor 3	Protein Coding	12.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16670281 9323208 9639073 (more) 16107768 9949155 12555203
27	FAS	Fas Cell Surface Death Receptor	Protein Coding	12.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8675212 7587741 7539037 (more) 8690919 11800643 9548519 10419894 15235202 8523526 16290071 7727211 9553736 8918700 9806031 11193040 16164692 8825755
28	CX3CR1	C-X3-C Motif Chemokine Receptor 1	Protein Coding	11.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12799549 12969992 16478397 (more) 12646802 11187812 12551893 17673719 11391174 12234253
29	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	11.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15592417 19529751
30	CD69	CD69 Molecule	Protein Coding	11.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18856207
31	CD79A	CD79a Molecule	Protein Coding	11.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7946101 1405320 9623918 (more) 16369464 7724026 2046411 7653407 18160012 9409634 7658060 11595287 8195616 8235446 2063023 2406346 16672546 11358543 7915975 8097416 12164661 8458962 1284355 14647586 11110704 7554205 9780421 1371157 12383203 7517378 11555159 9143176 8102854
32	TAT	Tyrosine Aminotransferase	Protein Coding	11.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19526283 15869407 15976177 (more) 8212135 15578978 16838299 10384093 15916041 17460112 8603259 18784333 15857508 7689227 16877296 16289656 11174904 10698152 1396975 18366309 15962513 11579140 16395283 16354571 15691386 10665489 18329615 15780141 14689754 11299302 11044099 16137881 12193009 9987082 15943860 11060751 16614257 18715150
33	CSF2	Colony Stimulating Factor 2	Protein Coding	11.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1492010 10770541 14673758 (more) 1713806 10397557 1701795 14575766 7904721 2043705 2198662 1380256 9209837 16352578
34	IL16	Interleukin 16	Protein Coding	11.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14741421 15989588 8902078 (more) 10787016 19251297 10395686 10535609 12734931 9127015
35	SERPINA3	Serpin Family A Member 3	Protein Coding	11.19	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	12468618 16630383
36	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	10.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1708315 9736739 2258606 (more) 8097416 1691289 1711311 9341758 2384263 9637477 9440820 16956389
37	CD80	CD80 Molecule	Protein Coding	10.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7690323 12468426 10403920 (more) 11390619 15272203 18524824
38	CCNT1	Cyclin T1	Protein Coding	10.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19886831 16330531
39	H2AC18	H2A Clustered Histone 18	Protein Coding	10.68	DISEASES inferred ¹⁴ ¹⁴
40	SELL	Selectin L	Protein Coding	10.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8671648 9886395 11101052
41	GZMB	Granzyme B	Protein Coding	10.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19692459 15090789
42	PDCD1	Programmed Cell Death 1	Protein Coding	10.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19564339 19442121 20208540 (more) 16954372 19420076
43	ADA	Adenosine Deaminase	Protein Coding	10.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10778623 20067539 20347569 (more) 8519829 7775940 16542154 8729768 9330696
44	IDO1	Indoleamine 2,3-Dioxygenase 1	Protein Coding	10.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17430111 15579280 17430110 (more) 7617307 19656212 15206745 1722946 20484731
45	CLEC4M	C-Type Lectin Domain Family 4 Member M	Protein Coding	10.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17530994 12152166 19046307 (more) 12738250
46	FCGR3A	Fc Gamma Receptor IIIa	Protein Coding	9.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18780233 10733511
47	MBL2	Mannose Binding Lectin 2	Protein Coding	9.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12640191 9014910 16313253 (more) 16500704 8666845 15488604 9293399 18495592 18498240 19275590 14614673 15117456 19796822 16960176 9863582 7743658 9584002 12715245
48	CCR8	C-C Motif Chemokine Receptor 8	Protein Coding	9.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16221874 12551893
49	CCR7	C-C Motif Chemokine Receptor 7	Protein Coding	9.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19455014
50	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	9.75	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Human Immunodeficiency Virus Infectious Disease

Sources

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Sources

Pathways for Human Immunodeficiency Virus Infectious Disease

Pathways directly related to Human Immunodeficiency Virus Infectious Disease:

(show all 49)

#	Pathway	Source
1	HIV Infection	Reactome ⁶⁶
2	HIV Life Cycle	Reactome ⁶⁶
3	Budding and maturation of HIV virion	Reactome ⁶⁶
4	Late Phase of HIV Life Cycle	Reactome ⁶⁶
5	Host Interactions of HIV factors	Reactome ⁶⁶
6	Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	Reactome ⁶⁶
7	Nef mediated downregulation of MHC class I complex cell surface expression	Reactome ⁶⁶
8	Vif-mediated degradation of APOBEC3G	Reactome ⁶⁶
9	Vpu mediated degradation of CD4	Reactome ⁶⁶
10	Formation of HIV elongation complex in the absence of HIV Tat	Reactome ⁶⁶
11	RNA Polymerase II HIV Promoter Escape	Reactome ⁶⁶
12	HIV Transcription Initiation	Reactome ⁶⁶
13	Transcription of the HIV genome	Reactome ⁶⁶
14	RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	Reactome ⁶⁶
15	Formation of the HIV-1 Early Elongation Complex	Reactome ⁶⁶
16	HIV Transcription Elongation	Reactome ⁶⁶
17	Tat-mediated elongation of the HIV-1 transcript	Reactome ⁶⁶
18	Formation of HIV-1 elongation complex containing HIV-1 Tat	Reactome ⁶⁶
19	Interactions of Tat with host cellular proteins	Reactome ⁶⁶
20	Pausing and recovery of HIV elongation	Reactome ⁶⁶
21	Pausing and recovery of Tat-mediated HIV elongation	Reactome ⁶⁶
22	Tat-mediated HIV elongation arrest and recovery	Reactome ⁶⁶
23	HIV elongation arrest and recovery	Reactome ⁶⁶
24	Rev-mediated nuclear export of HIV RNA	Reactome ⁶⁶
25	Vpr-mediated nuclear import of PICs	Reactome ⁶⁶
26	Nuclear import of Rev protein	Reactome ⁶⁶
27	Interactions of Vpr with host cellular proteins	Reactome ⁶⁶
28	Interactions of Rev with host cellular proteins	Reactome ⁶⁶
29	APOBEC3G mediated resistance to HIV-1 infection	Reactome ⁶⁶
30	Autointegration results in viral DNA circles	Reactome ⁶⁶
31	Integration of viral DNA into host genomic DNA	Reactome ⁶⁶
32	Early Phase of HIV Life Cycle	Reactome ⁶⁶
33	Integration of provirus	Reactome ⁶⁶
34	2-LTR circle formation	Reactome ⁶⁶
35	Nef Mediated CD8 Down-regulation	Reactome ⁶⁶
36	Nef mediated downregulation of CD28 cell surface expression	Reactome ⁶⁶
37	Nef Mediated CD4 Down-regulation	Reactome ⁶⁶
38	Binding and entry of HIV virion	Reactome ⁶⁶
39	Membrane binding and targetting of GAG proteins	Reactome ⁶⁶
40	Assembly Of The HIV Virion	Reactome ⁶⁶
41	Synthesis And Processing Of GAG, GAGPOL Polyproteins	Reactome ⁶⁶
42	Uncoating of the HIV Virion	Reactome ⁶⁶
43	Synthesis and processing of ENV and VPU	Reactome ⁶⁶
44	Minus-strand DNA synthesis	Reactome ⁶⁶
45	Nef and signal transduction	Reactome ⁶⁶
46	Plus-strand DNA synthesis	Reactome ⁶⁶
47	Reverse Transcription of HIV RNA	Reactome ⁶⁶
48	Abortive elongation of HIV-1 transcript in the absence of Tat	Reactome ⁶⁶
49	Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization	Reactome ⁶⁶

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14	TNF IL7R IL7 IL2 IL10 IFNG
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.87	TNF IL7R IL7 IL2 IL10 CXCR4
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.66	TNF IL7R IL7 IL2 IL10 IFNG
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.59	CCL3 CCL4 CCL5 CD4 CXCL12 CXCR4
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.49	CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.34	CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.26	B2M CCL3 CCL4 CCL5 CCR5 CD4
8	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.93	CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
9	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.91	TNF IL2 IFNA1 CD209 CCL5 CCL4
10	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.73	TNF IL7R IL2 IL10 IFNG IFNA1
11	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.68	TNF IFNG CXCR4 CD4 CCR5
12	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.61	TNF IL2 IL10 IFNG CD4
13	NF-kappaB Signaling ³	12.47	TNF IL2 IL10 IFNG IFNA1 CXCR4
14	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.23	TNF IL2 IL10 IFNG CD4
15	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	12.17	CXCR4 CXCL12 CCR5 CCL5 CCL4 CCL3
16	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.07	IL2 IFNG CD4 CCR5 CCL4 CCL3
17	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	12.03	TNF IL2 IL10 IFNG CD4
18	Allograft rejection ⁷⁴	11.98	CXCL12 IFNG IL10 IL2 TNF
19	CCL18 signaling pathway ⁷⁴	11.95	IL10 CXCR4 CCR5 CCL3
20	Acute viral myocarditis ⁷⁴	11.91	IL2 IL10 IFNG CXCR4 CD4 CCR5
21	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.85	TNF IL2 IL10 IFNG CXCR4 CXCL12
22	Burn wound healing ⁷⁴	11.76	TNF CXCR4 CXCL12
23	Lung fibrosis ⁷⁴	11.76	TNF CCL5 CCL4 CCL3
24	miRNAs involvement in the immune response in sepsis ⁷⁴	11.75	TNF IL10 CCL4 CCL3
25	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.73	TNF IL2 IL10 IFNG
26	Th17 cell differentiation pathway ⁷⁴	11.72	IL2 IFNG CD4
27	AP-1 transcription factor network ⁶¹	11.72	IL2 IL10 IFNG
28	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.7	TNF IL2 IFNG
29	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.69	CCL3 CCL4 CCL5 IL10 TNF
30	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.67	TNF IL2 IFNG
31	Innate Lymphoid Cells Differentiation ⁶⁵	11.66	CCL3 CD4 IFNG IL10 IL2 IL7
32	THC Differentiation Pathway ⁶⁴	11.63	TNF IL2 IL10 IFNG CD4
33	CXCR4-mediated signaling events ⁶¹	11.62	CXCR4 CXCL12 CD4
34	Interleukin-10 signaling ⁶⁶	11.61	TNF IL10 CCR5 CCL5 CCL4 CCL3
35	Th2 Differentiation ⁶⁵	11.6	IL2 IL10 IFNG CD4
36	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.44	TNF IL2 IL10 IFNG CCL4 CCL3
37	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.43	TNF IL7R IL2 IL10 IFNG CD4
38	Interactions of natural killer cells in pancreatic cancer ⁷⁴	11.38	TNF IFNG CCL5 CCL4 CCL3
39	Development and heterogeneity of the ILC family ⁷⁴	11.36	TNF IL7 IFNG
40	Syndecan-4-mediated signaling events ⁶¹	11.35	CCL5 CXCL12 CXCR4
41	Immune infiltration in pancreatic cancer ⁷⁴	11.34	TNF IL2 IL10 IFNG
42	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.34	TNF IL7R IL7 IL2 IL10 IFNG
43	Prostaglandin signaling ⁷⁴	11.3	TNF IFNA1 CCL3
44	IL12 signaling mediated by STAT4 ⁶¹	11.28	IL2 IFNG CD4
45	OX40 Pathway ⁶⁴	11.26	IL2 IL10 IFNG
46	Cytokines and inflammatory response ⁷⁴	11.26	TNF IL7 IL2 IL10 IFNG CD4
47	G-protein signaling_Rap2B regulation pathway ²²	11.1	TNF IL7 IL2 IL10 CXCL12 CCL5
48	Selective expression of chemokine receptors during T-cell polarization ⁷⁴	11.01	IL2 IFNG CD4 CCR5 CCL4
49	RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) ⁶⁶	10.71	IL2 IFNG
50	COVID-19 adverse outcome pathway ⁷⁴	10.71	IL2 CCL3

Sources

GO Terms for Human Immunodeficiency Virus Infectious Disease

Cellular components related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.23	B2M CCL3 CCL4 CCL5 CD9 CXCL12
2	extracellular region	GO:0005576	10.12	B2M CCL3 CCL4 CCL5 CD209 CD9
3	cell surface	GO:0009986	10.03	TNF CXCR4 CD4 CD38 CD209 CCR5
4	external side of plasma membrane	GO:0009897	9.58	TNF IL7R CXCR4 CXCL12 CD9 CD4

Biological processes related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 44)

#	Name	GO ID	Score	Top Affiliating Genes
1	inflammatory response	GO:0006954	10.44	CCL3 CCL4 CCL5 CCR5 CXCR4 TNF
2	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.34	TNF CD4 CCL5 CCL4 CCL3
3	signal transduction	GO:0007165	10.3	CCL3 CCL4 CCL5 CCR5 CD38 CD4
4	MAPK cascade	GO:0000165	10.28	TNF CCR5 CCL5 CCL3
5	cell-cell signaling	GO:0007267	10.27	CCL3 CCL4 CCL5 CCR5 IL2 IL7
6	positive regulation of inflammatory response	GO:0050729	10.25	CCL3 IFNG IL2 TNF
7	viral entry into host cell	GO:0046718	10.25	CXCR4 CD4 CD209 CCR5
8	cellular response to type II interferon	GO:0071346	10.22	CCL3 CCL4 CCL5 TNF
9	regulation of insulin secretion	GO:0050796	10.17	TNF IFNG CCL5
10	response to activity	GO:0014823	10.17	TNF IL10 CXCR4
11	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	10.17	CCL5 IFNG IL2 TNF
12	positive regulation of B cell proliferation	GO:0030890	10.16	IL7 IL2 CD38
13	monocyte chemotaxis	GO:0002548	10.16	CCL5 CCL4 CCL3
14	positive regulation of chemokine production	GO:0032722	10.16	TNF IL7 IFNG
15	calcium-mediated signaling	GO:0019722	10.16	CCL3 CCR5 CD4 CXCR4 TNF
16	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.14	TNF CCL5 CCL3
17	humoral immune response	GO:0006959	10.14	IFNA1 IFNG IL7 TNF
18	lymphocyte chemotaxis	GO:0048247	10.13	CCL5 CCL4 CCL3
19	positive regulation of calcium ion transport	GO:0051928	10.09	CCL5 CCL4 CCL3
20	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.08	TNF IL7R IL10 CCL5
21	T cell differentiation	GO:0030217	10.07	CD4 IL2 IL7R
22	chemotaxis	GO:0006935	10.07	CCL3 CCL4 CCL5 CCR5 CXCL12 CXCR4
23	defense response	GO:0006952	10.06	TNF IFNA1 CXCL12 CCR5
24	positive regulation of calcium-mediated signaling	GO:0050850	10.05	CD4 CCL4 CCL3
25	eosinophil chemotaxis	GO:0048245	10.03	CCL5 CCL4 CCL3
26	cell chemotaxis	GO:0060326	10.03	CXCR4 CXCL12 CCR5 CCL5 CCL3
27	response to virus	GO:0009615	10.03	TNF IFNG CXCR4 CXCL12 CCL5 CCL4
28	dendritic cell chemotaxis	GO:0002407	10.02	CXCR4 CCR5 CCL5
29	regulation of calcium ion transport	GO:0051924	10.01	CXCR4 CXCL12 CD4
30	signaling	GO:0023052	10	TNF CCR5 CCL3
31	detection of mechanical stimulus involved in sensory perception of pain	GO:0050966	10	TNF CXCR4 CXCL12
32	negative regulation by host of viral transcription	GO:0043922	9.99	CCL5 CCL4 CCL3
33	negative regulation of cytokine production involved in immune response	GO:0002719	9.97	TNF IL10
34	telencephalon cell migration	GO:0022029	9.97	CXCR4 CXCL12
35	positive regulation of plasma cell differentiation	GO:1900100	9.94	IL2 IL10
36	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.93	TNF IFNG
37	positive regulation of nitrogen compound metabolic process	GO:0051173	9.93	TNF IFNG
38	chronic inflammatory response to antigenic stimulus	GO:0002439	9.9	IL10 TNF
39	positive regulation of vitamin D biosynthetic process	GO:0060557	9.89	IFNG TNF
40	response to ultrasound	GO:1990478	9.88	CXCL12 CXCR4
41	positive regulation of natural killer cell chemotaxis	GO:2000503	9.88	CCL5 CCL4 CCL3
42	B cell proliferation	GO:0042100	9.85	CD38 IFNA1 IL10 IL7 IL7R
43	chemokine-mediated signaling pathway	GO:0070098	9.7	CXCR4 CXCL12 CCR5 CCL5 CCL4 CCL3
44	immune response	GO:0006955	9.64	TNF IL7R IL7 IL2 IL10 IFNG

Molecular functions related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	virus receptor activity	GO:0001618	9.92	CXCR4 CD4 CD209 CCR5
2	coreceptor activity	GO:0015026	9.88	CXCR4 CD4 CCR5
3	chemokine activity	GO:0008009	9.86	CXCL12 CCL5 CCL4 CCL3
4	CCR chemokine receptor binding	GO:0048020	9.85	CCL5 CCL4 CCL3
5	CCR5 chemokine receptor binding	GO:0031730	9.63	CCL3 CCL4 CCL5
6	cytokine activity	GO:0005125	9.55	TNF IL7 IL2 IL10 IFNG IFNA1
7	CCR1 chemokine receptor binding	GO:0031726	9.43	CCL5 CCL4 CCL3